Rplp1 bypasses replicative senescence and contributes to transformation

Experimental Cell Research

Volumn 315, Issue 8, 2009, Pages 1372-1383

  Artero Castro, A ^a   Kondoh, H ^b   Fernandez Marcos P J ^c   Serrano, M ^c   y Cajal, S Ramón ^a   LLeonart, M E ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b KYOTO UNIVERSITY   (Japan)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Cancer; Cellular aging and senescence; Embryonic stem cells; Ribosomal proteins

Indexed keywords

COMPLEMENTARY DNA; CYCLIN E; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53; RAS PROTEIN; RIBOSOME PROTEIN; RIBOSOME PROTEIN RPLP1; UNCLASSIFIED DRUG; VALINE;

AGAR MEDIUM; ANIMAL CELL; ARTICLE; CELL AGING; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; COLON CANCER; CONTROLLED STUDY; DNA LIBRARY; EMBRYO; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MUTANT; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR BIOPSY; UPREGULATION;

EID: 64049083100     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.02.007     Document Type: Article

References (53)

1. Kondoh H., LLeonart M.E., Nakashima Y., Yokode M., Tanaka M., Bernard D., Gil J., and Beach D. A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid. Redox. Signal. 9 (2007) 293-299
2. Zeng X., and Rao M.S. Human embryonic stem cells: long term stability, absence of senescence and a potential cell source for neural replacement. Neuroscience 145 (2007) 1348-1358
3. Miura T., Mattson M.P., and Rao M.S. Cellular lifespan and senescence signaling in embryonic stem cells. Aging Cell 3 (2004) 333-343
4. Hannon G.J., Sun P., Carnero A., Xie L.Y., Maestro R., Conklin D.S., and Beach D. MaRX: an approach to genetics in mammalian cells. Science 283 (1999) 1129-1130
5. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., Agami R., Ge W., Cavet G., Linsley P.S., Beijersbergen R.L., and Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004) 431-437
6. Kondoh H., LLeonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., and Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 65 (2005) 177-185
7. Remacha M., Jimenez-Diaz A., Santos C., Briones E., Zambrano R., Rodriguez Gabriel M.A., Guarinos E., and Ballesta J.P. Proteins P1, P2, and P0, components of the eukaryotic ribosome stalk, New structural and functional aspects. Biochem. Cell. Biol. 73 (1995) 959-968
8. Ruggero D., and Pandolfi P.P. Does the ribosome translate cancer?. Nat. Rev. Cancer 3 (2003) 179-192
9. Wool I.G. Extraribosomal functions of ribosomal proteins. Trends Biochem. Sci. 21 (1996) 164-165
10. Bhat K.P., Itahana K., Jin A., and Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23 (2004) 2402-2412
11. Dai M.S., Zeng S.X., Jin Y., Sun X.X., David L., and Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 24 (2004) 7654-7668
12. Lohrum M.A., Ludwig R.L., Kubbutat M.H., Hanlon M., and Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3 (2003) 577-587
13. Dai M.S., and Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279 (2004) 44475-44482
14. Dai M.S., Arnold H., Sun X.X., Sears R., and Lu H. Inhibition of c-Myc activity by ribosomal protein L11. EMBO J. 26 (2007) 3332-3345
15. Welsh J.B., Zarrinkar P.P., Sapinoso L.M., Kern S.G., Behling C.A., Monk B.J., Lockhart D.J., Burger R.A., and Hampton G.M. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 98 (2001) 1176-1181
16. Chiao P.J., Shin D.M., Sacks P.G., Hong W.K., and Tainsky M.A. Elevated expression of the ribosomal protein S2 gene in human tumors. Mol. Carcinog. 5 (1992) 219-231
17. Wang H., Zhao L.N., Li K.Z., Ling R., Li X.J., and Wang L. Overexpression of ribosomal protein L15 is associated with cell proliferation in gastric cancer. BMC Cancer 6 (2006) 91
18. Zhang L., Zhou W., Velculescu V.E., Kern S.E., Hruban R.H., Hamilton S.R., Vogelstein B., and Kinzler K.W. Gene expression profiles in normal and cancer cells. Science 276 (1997) 1268-1272
19. Chung E.J., Sung Y.K., Farooq M., Kim Y., Im S., Tak W.Y., Hwang Y.J., Kim Y.I., Han H.S., Kim J.C., and Kim M.K. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol. Cells 14 (2002) 382-387
20. Bee A., Ke Y., Forootan S., Lin K., Beesley C., Forrest S.E., and Foster C.S. Ribosomal protein l19 is a prognostic marker for human prostate cancer. Clin. Cancer Res. 12 (2006) 2061-2065
21. Huang X.P., Zhao C.X., Li Q.J., Cai Y., Liu F.X., Hu H., Xu X., Han Y.L., Wu M., Zhan Q.M., and Wang M.R. Alteration of RPL14 in squamous cell carcinomas and preneoplastic lesions of the esophagus. Gene 366 (2006) 161-168
22. Kobayashi T., Sasaki Y., Oshima Y., Yamamoto H., Mita H., Suzuki H., Toyota M., Tokino T., Itoh F., Imai K., and Shinomura Y. Activation of the ribosomal protein L13 gene in human gastrointestinal cancer. Int. J. Mol. Med. 18 (2006) 161-170
23. Ferrari S., Tagliafico E., Manfredini R., Grande A., Rossi E., Zucchini P., Torelli G., and Torelli U. Abundance of the primary transcript and its processed product of growth-related genes in normal and leukemic cells during proliferation and differentiation. Cancer Res. 52 (1992) 11-16
24. Uechi T., Tanaka T., and Kenmochi N. A complete map of the human ribosomal protein genes: assignment of 80 genes to the cytogenetic map and implications for human disorders. Genomics 72 (2001) 223-230
25. Bordogna W., Hudson J.D., Buddle J., Bennett D.C., Beach D.H., and Carnero A. EMX homeobox genes regulate microphthalmia and alter melanocyte biology. Exp. Cell. Res. 311 (2005) 27-38
26. Carnero A., Hudson J.D., Price C.M., and Beach D.H. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat. Cell. Biol. 2 (2000) 148-155
27. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E., Linskens M., Rubelj I., Pereira-Smith O., and Peacoke M. J. Campisi A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92 (1995) 9363-9367
28. Vilella M.D., Remacha M., Ortiz B.L., Mendez E., and Ballesta J.P. Characterization of the yeast acidic ribosomal phosphoproteins using monoclonal antibodies. Proteins L44/L45 and L44′ have different functional roles. Eur. J. Biochem. 196 (1991) 407-414
29. Neuman E., Flemington E.K., Sellers W.R., and Kaelin Jr.W.G. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 14 (1994) 6607-6615
30. LLeonart M.E., Vidal F., Gallardo D., Diaz-Fuertes M., Rojo F., Cuatrecasas M., Lopez-Vicente L., Kondoh H., Blanco C., Carnero A., and Ramon y Cajal S. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncol. Rep. 16 (2006) 603-608
31. Saito S., Liu B., and Yokoyama K. Animal embryonic stem (ES) cells: self-renewal, pluripotency, transgenesis and nuclear transfer. Hum. Cell. 17 (2004) 107-115
32. Moorthamer M., and Chaudhuri B. Identification of ribosomal protein L34 as a novel Cdk5 inhibitor. Biochem. Biophys. Res. Commun. 255 (1999) 631-638
33. Sherr C.J., and McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2 (2002) 103-112
34. Kamata H., Mitani S., Fujiwara M., Aoki N., Okada S., and Mori S. Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas. Clin. Exp. Med. 7 (2007) 39-46
35. Loging W.T., and Reisman D. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53. Cancer Epidemiol. Biomarkers Prev. 8 (1999) 1011-1016
36. Castro M.E., Leal J.F., LLeonart M.E., Ramon Y.C.S., and Carnero A. Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis 29 (2008) 1343-1350
37. Polager S., and Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol. 18 (2008) 528-535
38. Zhang S.Y., Liu S.C., Johnson D.G., and Klein-Szanto A.J. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res. 60 (2000) 5972-5976
39. Zhang S.Y., Liu S.C., Al-Saleem L.F., Holloran D., Babb J., Guo X., and Klein-Szanto A.J. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 395-401
40. Hallstrom T.C., Mori S., and Nevins J.R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13 (2008) 11-22
41. Davis J.N., Wojno K.J., Daignault S., Hofer M.D., Kuefer R., Rubin M.A., and Day M.L. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 66 (2006) 11897-11906
42. Nahle Z., Polakoff J., Davuluri R.V., McCurrach M.E., Jacobson M.D., Narita M., Zhang M.Q., Lazebnik Y., Bar-Sagi D., and Lowe S.W. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell. Biol. 4 (2002) 859-864
43. Suzuki M., Okuyama S., Okamoto S., Shirasuna K., Nakajima T., Hachiya T., Nojima H., Sekiya S., and Oda K. A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer. Oncogene 17 (1998) 853-865
44. Kim E., and Deppert W. Transcriptional activities of mutant p53: when mutations are more than a loss. J. Cell. Biochem. 93 (2004) 878-886
45. Sigal A., and Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60 (2000) 6788-6793
46. Kandioler D., Stamatis G., Eberhardt W., Kappel S., Zochbauer-Muller S., Kuhrer I., Mittlbock M., Zwrtek R., Aigner C., Bichler C., Tichy V., Hudec M., Bachleitner T., End A., Muller M.R., Roth E., and Klepetko W. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 135 (2008) 1036-1041
47. He H., and Sun Y. Ribosomal protein S27L is a direct p53 target that regulates apoptosis. Oncogene 26 (2007) 2707-2716
48. Lindstrom M.S., Jin A., Deisenroth C., White Wolf G., and Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol. 27 (2007) 1056-1068
49. Nusspaumer G., Remacha M., and Ballesta J.P. Phosphorylation and N-terminal region of yeast ribosomal protein P1 mediate its degradation, which is prevented by protein P2. EMBO J. 19 (2000) 6075-6084
50. Alonso M.M., Alemany R., Fueyo J., and Gomez-Manzano C. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett. 263 (2008) 157-163
51. Nowak K., Kerl K., Fehr D., Kramps C., Gessner C., Killmer K., Samans B., Berwanger B., Christiansen H., and Lutz W. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 34 (2006) 1745-1754
52. Keyomarsi K., Tucker S.L., Buchholz T.A., Callister M., Ding Y., Hortobagyi G.N., Bedrosian I., Knickerbocker C., Toyofuku W., Lowe M., Herliczek T.W., and Bacus S.S. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347 (2002) 1566-1575
53. Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., and Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3 (1997) 222-225